Funder: ALEXION PHARMA SPAIN, SL
date_range Duration: from 19 May 2023 to 30 November 2023 (6 months) Finished
euro 7,308.40 EUR

Of National scope.

Análisis de datos clínicos y farmacológicos de los medicamentos biosimilares de eculizumab.

Call: (ALEXION PHARMA SPAIN, SL)

Researchers